高级搜索
不同佐剂增强小鼠黑色素瘤瘤苗抗瘤细胞免疫效应的比较[J]. 肿瘤防治研究, 2007, 34(04): 259-261. DOI: 10.3971/j.issn.1000-8578.589
引用本文: 不同佐剂增强小鼠黑色素瘤瘤苗抗瘤细胞免疫效应的比较[J]. 肿瘤防治研究, 2007, 34(04): 259-261. DOI: 10.3971/j.issn.1000-8578.589
The Cell-mediated Immunoenhancement of Different Adjuvants on the Murine Melanoma Vaccine[J]. Cancer Research on Prevention and Treatment, 2007, 34(04): 259-261. DOI: 10.3971/j.issn.1000-8578.589
Citation: The Cell-mediated Immunoenhancement of Different Adjuvants on the Murine Melanoma Vaccine[J]. Cancer Research on Prevention and Treatment, 2007, 34(04): 259-261. DOI: 10.3971/j.issn.1000-8578.589

不同佐剂增强小鼠黑色素瘤瘤苗抗瘤细胞免疫效应的比较

The Cell-mediated Immunoenhancement of Different Adjuvants on the Murine Melanoma Vaccine

  • 摘要: 目的 评价5种不同配方佐荆在低免疫原性小鼠黑色素瘤瘤苗保护性免疫中的细胞免疫增强作用。方法 实验组用5种不同配方的佐剂(FCA,FCA+IL-2+GM-CSF,FIA+IL-2+GM-CSF,FIA+SWZY,FIA+SWZY+IL-2+GM-CSF)和照射灭活的D5黑色素瘤细胞制成瘤苗免疫小鼠,对照组免疫用单纯灭活D5黑色素瘤细胞。末次免疫后3天各组取半数动物检测DTH反应、NK细胞活性及特异性CTL活性,剩余半数动物接种活D5黑色素瘤细胞,3周后再次检测上述各免疫学参数。结果 与对照组相比,经免疫后的各实验组DTH反应、NK细胞活性、CTL活性均明显升高(P〈0.05),但成瘤后随肿瘤增大,则呈下降趋势。结论 5种佐剂配方制成的瘤苗均能诱导免疫小鼠对低免疫原性肿瘤的细胞免疫应答。其中佐剂SWZY和FCA增强免疫的效果相当,而毒副作用较小,可望成为一种人类肿瘤免疫治疗的新型佐剂。

     

    Abstract: Objective  To investigate the cell-mediated immunity enhancement effect of different adjuvants on the immunoprevention of poorly immunogenic murine melanoma vaccine. Methods  Mice were immunized with inactivited D5 melanoma cells combined with five different adjuvant s ( FCA 、FCA + IL-2 +GM-CSF 、FIA + IL-2 + GM-CSF、FIA+SWZY、FIA + SWZY + IL-2 + GM-CSF) respectively and the control without adjuvants. 3 days after immunization, DTH response 、NK cell activity and specific CTL activity were assayed in half of the mice. The rest were inoculated with the live D5 tumor cells, 3 weeks after tumor inoculation, the same immunological parameters were measured. Results  DTH response, NK cell activity and CTL activity of all the experimental groups were higher than that in the control group ( P < 0. 05), but decreased after the tumor grew larger. Conclusion  Adjuvant FCA, FIA, IL-2, GM-CSF, SWZY could enhance the cell-mediated immune responses against poorly immunogenic tumor.The adjuvant SWZY could st rengthen immunoresponses similar to FCA, but had almost no harmful sideeffect, which might be a promising adjuvant for cancer vaccine.

     

/

返回文章
返回